Partners Healthcare and Medison Pharma-backed Keros Therapeutics floated at the top of its range and will look to advance its musculoskeletal disorder drug candidates.
Keros Therapeutics, a US-based musculoskeletal disorder treatment developer backed by pharmaceutical services provider Medison Pharma and healthcare provider Partners Healthcare, floated yesterday in a $96m initial public offering.
The company increased the number of shares in the offering from 5 million to 6 million and priced them at the top of the IPO’s $14 to $16 range. It was valued at approximately $306m in the IPO.
Keros is developing drugs to treat musculoskeletal and haematological disorders with a high…
